<DOC>
	<DOCNO>NCT01387737</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy TA-7284 monotherapy combination therapy oral anti-hyperglycaemic agent Japanese patient Type 2 diabetes mellitus 52 week oral administration .</brief_summary>
	<brief_title>Long-Term Safety Study TA-7284 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This randomize , 2-arm , parallel group , open-label study evaluate safety efficacy TA-7284 Japanese patient Type 2 diabetes mellitus , optimally control diet exercise oral anti-hyperglycaemic agent . The patient receive either TA-7284-Low TA-7284-High orally alone combination oral anit-hyperglycaemic agent 52 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Men woman age ≥20 year old Diagnosed Type 2 diabetes mellitus least 3 month screen HbA1c ≥7.0 % ≤10.0 % ( monotherapy group ) HbA1c ≥7.0 % ≤10.5 % ( combination therapy group ) Type I diabetes mellitus , diabetes mellitus result pancreatic disorder , secondary diabetes mellitus Past current history severe diabetic complication Fasting plasma glucose &gt; 270 mg/dL treatment start History hereditary glucosegalactose malabsorption primary renal glucosuria Patients require insulin therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>TA-7284</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Sodium Glucose Co-Transporter ( SGLT2 inhibitor )</keyword>
</DOC>